Last updated: August 21, 2026
Lamisil is a terbinafine-based antifungal brand with limited remaining exclusivity value and a large generic market. The main commercial opportunity is not basic terbinafine substitution. It is differentiated delivery: improved skin residence, nail penetration, pediatric dosing, tolerability, packaging, and consumer convenience. Excipient selection can support these claims, but most opportunities require clinical, sensory, stability, or performance data rather than excipient novelty alone.
What products and dosage forms does Lamisil contain?
Lamisil contains terbinafine hydrochloride, an allylamine antifungal. The product has been commercialized in oral and topical dosage forms, with product availability varying by country.
| Product type |
Active ingredient |
Typical use |
Regulatory status |
| Oral tablet |
Terbinafine hydrochloride equivalent to terbinafine |
Onychomycosis and systemic dermatophyte infections |
Prescription drug |
| Topical cream |
Terbinafine hydrochloride |
Tinea pedis, tinea cruris, tinea corporis |
OTC in some markets, including the U.S. |
| Topical spray or solution |
Terbinafine hydrochloride |
Superficial dermatophyte infections |
OTC or pharmacy product, depending on jurisdiction |
| Topical gel or film-forming product |
Terbinafine hydrochloride |
Skin fungal infections |
Market-specific |
| Granules or pediatric formulations |
Terbinafine hydrochloride |
Pediatric fungal infections in selected markets |
Market-specific |
The U.S. oral product was approved under NDA 20-539 for terbinafine hydrochloride tablets. The U.S. topical OTC product is regulated under the FDA’s OTC antifungal monograph framework, subject to the applicable final monograph requirements and labeling controls.[1][2]
What excipients are used in Lamisil tablets?
Lamisil tablets use conventional direct-compression or dry-blending excipients. Public product labeling identifies excipient classes including microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and coating materials such as hypromellose, talc, titanium dioxide, and colorants.[3]
Oral tablet excipient functions
| Excipient class |
Typical function |
Commercial relevance |
| Microcrystalline cellulose |
Diluent and compression aid |
Supports tablet hardness and manufacturability |
| Sodium starch glycolate |
Superdisintegrant |
Controls disintegration and dissolution |
| Colloidal silicon dioxide |
Glidant |
Improves powder flow |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force |
| Hypromellose |
Film former |
Protects the tablet and improves appearance |
| Talc |
Anti-adherent and coating aid |
Supports coating process |
| Titanium dioxide or iron oxides |
Opacifier or colorant |
Supports product identification and light protection |
The tablet formulation is difficult to differentiate through routine excipient substitution. A generic manufacturer can generally match performance using standard compendial materials. The principal development risks are blend uniformity, compression behavior, dissolution, coating robustness, stability, and impurity control.
What tablet excipient changes could create commercial value?
Potential value exists where an excipient change addresses a defined product problem:
- Lower magnesium stearate concentration to reduce hydrophobic impact on dissolution.
- Use of co-processed excipients to improve compressibility and reduce tablet weight.
- Colorant-free coating for patients with sensitivity or for markets with restricted colorant preferences.
- Moisture-barrier packaging combined with a lower-hygroscopicity formulation.
- Smaller tablets for adherence-sensitive patients.
- Orally disintegrating or sprinkle-compatible products, subject to bioequivalence and regulatory requirements.
- Pediatric multiparticulates with taste masking.
A tablet reformulation will not automatically obtain meaningful intellectual property. A composition claim must distinguish the product through defined quantitative ranges, performance characteristics, manufacturing parameters, or clinically relevant advantages.
What excipients are used in Lamisil topical products?
Lamisil topical products use emulsions, solvents, surfactants, fatty alcohols, penetration aids, preservatives, alkalizing agents, and water. Public labels for terbinafine cream products identify excipients such as benzyl alcohol, cetyl alcohol, cetyl palmitate, isopropyl myristate, polysorbate 60, sodium hydroxide, sorbitan monostearate, stearyl alcohol, and purified water.[4]
The exact excipient profile differs by product, manufacturer, country, and dosage form. Generic topical products may use different emulsifier systems while maintaining the same active concentration and therapeutic category.
Topical excipient functions
| Excipient |
Primary role |
Development issue |
| Benzyl alcohol |
Preservative and solvent |
Irritation, sensitization, pediatric exposure |
| Cetyl and stearyl alcohols |
Consistency agents and emollients |
Texture, phase behavior, skin feel |
| Isopropyl myristate |
Emollient and penetration aid |
Irritation, comedogenicity, migration into packaging |
| Polysorbate 60 |
Emulsifier |
Compatibility and oxidative stability |
| Sorbitan monostearate |
Co-emulsifier |
Emulsion stability |
| Sodium hydroxide |
pH adjustment |
Skin tolerability and preservative performance |
| Purified water |
Continuous phase |
Microbial control and stability |
The commercial differentiation potential is higher for topical products than for tablets because vehicle properties directly affect consumer experience, application behavior, residence time, and willingness to complete treatment.
What formulation patents could protect a Lamisil follow-on product?
A follow-on terbinafine product can pursue protection around the formulation, process, device, packaging, or use. The active ingredient itself is long established, so an API-centered patent strategy is unlikely to provide strong exclusion.
Formulation patent categories
Emulsion and cream systems
Claims may cover:
- Specific oil-to-water ratios.
- Defined emulsifier combinations.
- Narrow pH ranges.
- Preservative-free systems.
- Reduced-irritancy vehicles.
- Particle-size distributions.
- Enhanced skin deposition.
- Improved terbinafine release or permeation.
- Long-term physical stability.
- Reduced crystallization of terbinafine hydrochloride.
A robust formulation patent should connect the excipient combination to measurable results, such as higher skin retention, lower transepidermal loss, faster lesion clearance, reduced irritation, or improved stability.
Hydroalcoholic sprays and solutions
Spray products can be differentiated by:
- Ethanol or propylene glycol concentration.
- Volatile solvent systems.
- Solubilizers.
- Drying time.
- Spray plume and droplet size.
- Reduced stinging on fissured skin.
- Non-aerosol pump design.
- Dose uniformity per actuation.
Device and formulation claims can be filed separately. The device may have greater commercial value when the formulation is easy to replicate.
Film-forming systems
A terbinafine film-forming solution can use polymers such as acrylates, cellulose derivatives, or other film-forming materials. Commercial claims may focus on:
- One-application or reduced-frequency dosing.
- Longer residence time.
- Water resistance.
- Reduced transfer to clothing.
- Improved coverage of interdigital spaces.
- Controlled terbinafine release.
These products require evidence that the film does more than increase cosmetic persistence. The development package should establish drug delivery, clinical exposure, and therapeutic equivalence.
Nail-delivery systems
Onychomycosis is a more difficult delivery problem than superficial skin infection. Opportunity areas include:
- Keratin-penetrating solvents.
- Nail-permeation enhancers.
- Hydrophilic or amphiphilic polymers.
- Occlusive or semi-occlusive systems.
- Nail lacquer or brush-on delivery.
- Microparticle or nanosuspension systems.
- Combination delivery with urea or other keratolytic excipients.
A nail product may support a higher price than conventional cream, but it faces a longer development cycle and more demanding clinical differentiation.
How strong is the Lamisil patent estate?
The original terbinafine and early Lamisil composition patents are expired or commercially exhausted in major markets. Current barriers are more likely to arise from regulatory requirements, trademarks, product-specific formulation rights, manufacturing know-how, and market access than from a broad blocking patent on terbinafine.
| IP category |
Current strategic value |
| Terbinafine active-ingredient patents |
Low in major generic markets |
| Original oral tablet patents |
Low |
| Basic terbinafine cream patents |
Low |
| New topical vehicle patents |
Moderate to high if supported by data |
| Nail-delivery patents |
Moderate to high |
| Pediatric dosage-form patents |
Moderate |
| Device and packaging patents |
Moderate |
| Lamisil trademark and trade dress |
Commercially relevant |
| Manufacturing know-how |
Relevant where impurity control or scale-up is difficult |
Patent strength depends on claim scope, prosecution history, prior art, geographic coverage, and whether the claims cover a commercially necessary formulation. A narrow claim to a small excipient range may be easy to design around unless the range is linked to a strong performance result.
When did Lamisil lose exclusivity?
Lamisil’s core market exclusivity has ended in major jurisdictions. Generic terbinafine tablets have been available for many years, and multiple manufacturers supply terbinafine topical products.
The relevant commercial distinction is between:
- Loss of original product exclusivity.
- Continued brand recognition.
- Product-specific OTC monograph status.
- Any later formulation or device protection.
- Market-specific regulatory barriers.
The FDA lists approved generic terbinafine tablets and topical terbinafine products through its drug approval and labeling databases.[1][5] Exact market entry dates and current marketing status differ by manufacturer and dosage form.
What is the Orange Book status of Lamisil?
The U.S. Orange Book is relevant primarily to the prescription oral tablet product, not to all OTC topical Lamisil products. Orange Book listings can change when products are discontinued, withdrawn, or converted to different regulatory pathways.[1]
For a generic oral terbinafine applicant, the commercial analysis should examine:
- Whether the reference listed drug remains available for ANDA reference purposes.
- Whether any patent or exclusivity information remains listed.
- Whether the product is eligible for a standard ANDA.
- Whether a discontinued reference product requires a suitability or petition strategy.
- Whether the proposed dosage form and strength match the reference product.
Because the core oral product is mature, Paragraph IV litigation risk is generally lower than for recently approved branded products. A current Orange Book and FDA labeling review remains necessary before filing or licensing decisions.
Which companies are challenging Lamisil?
Generic competition comes from pharmaceutical manufacturers that supply terbinafine hydrochloride tablets, creams, gels, sprays, and solutions. The competitive field includes large generic companies, regional manufacturers, contract development and manufacturing organizations, and private-label OTC suppliers.
The market is fragmented by dosage form:
| Segment |
Competitive intensity |
Main differentiator |
| 250 mg oral tablets |
High |
Cost, supply reliability, regulatory compliance |
| 1% cream |
High |
Texture, packaging, retail price |
| Spray and solution |
Moderate to high |
Application convenience and drying time |
| Gel |
Moderate |
Skin feel and residence time |
| Nail products |
Lower |
Penetration evidence and treatment duration |
| Pediatric products |
Lower |
Taste masking, dosing, safety, regulatory pathway |
The principal competitive threat to a new Lamisil-related product is usually not an ANDA filer. It is a lower-priced generic or a branded OTC product with better consumer convenience.
What generic entry risks exist for Lamisil?
Generic entry risk is high for conventional oral and topical products. The main risks are commercial rather than patent-based.
Oral products
Generic manufacturers can compete through:
- Low-cost tablets.
- Pharmacy substitution.
- Hospital and managed-care contracting.
- Reliable supply during shortages.
- Simple packaging and high-volume production.
The branded product may retain demand through physician familiarity and consumer recognition, but price erosion is structural.
Topical products
Topical substitution is less automatic because patients evaluate:
- Greasiness.
- Absorption speed.
- Odor.
- Residue.
- Stinging.
- Ease of application.
- Tube and pump design.
- Duration of treatment.
A differentiated vehicle can therefore retain pricing even after active-ingredient exclusivity ends.
What excipient strategy offers the best commercial opportunity?
The strongest near-term opportunity is a topical, consumer-oriented product that improves application and adherence without creating a high regulatory burden.
Priority opportunity matrix
| Opportunity |
Excipient strategy |
Regulatory burden |
Commercial potential |
| Premium terbinafine cream |
Low-irritancy emulsion and improved sensory profile |
Moderate |
High |
| Fast-drying spray |
Volatile solvent and controlled spray system |
Moderate |
Moderate to high |
| Film-forming solution |
Polymer-based residence enhancement |
Moderate to high |
High |
| Nail treatment |
Permeation-enhancing vehicle |
High |
High but slower |
| Pediatric granules |
Taste masking and flexible dosing |
High |
Moderate |
| Preservative-free cream |
Self-preserving emulsion or single-dose packaging |
Moderate |
Moderate |
| Antifungal foot-care line |
Terbinafine with deodorizing or barrier-support excipients |
Market and regulatory dependent |
Moderate |
Best near-term target: improved topical cream
A premium cream can use:
- Lower-irritancy preservative systems.
- Reduced residual greasiness.
- Faster rub-in.
- Better spreading over large skin areas.
- Improved packaging for controlled dosing.
- Moisture management without excessive occlusion.
The patent package should combine composition claims, manufacturing claims, packaging claims, and data showing improved user-relevant performance.
Higher-value target: nail delivery
Nail delivery has greater unmet need and pricing potential. It also has greater technical risk. The formulation must balance terbinafine solubility, nail penetration, evaporation, cosmetic acceptability, and dosing persistence. A successful product could compete against ciclopirox, efinaconazole, amorolfine, and terbinafine off-label or systemic treatment rather than against cream alone.[6]
What manufacturing and IP barriers affect a Lamisil follow-on product?
The main manufacturing barriers are manageable but can affect scale-up and product quality.
Oral manufacturing barriers
- Blend segregation at low drug loading.
- Tablet capping or sticking.
- Lubrication-related dissolution changes.
- Coating uniformity.
- Residual solvent and impurity control.
- Packaging moisture protection.
Topical manufacturing barriers
- Emulsion phase inversion.
- Terbinafine crystallization.
- Preservative distribution.
- Viscosity drift.
- Air incorporation during homogenization.
- Microbial control.
- Tube or pump compatibility.
- Scale-dependent mixing differences.
Know-how can be more defensible than a basic excipient list. A process patent or trade secret covering order of addition, temperature profile, homogenization energy, cooling rate, or crystallization control may create a practical manufacturing advantage.
What licensing deals are relevant to Lamisil excipient opportunities?
Lamisil itself is a mature brand, so licensing value is more likely to arise from platform technology than from the terbinafine molecule. Potential licensing structures include:
- In-licensing a nail-permeation platform.
- Out-licensing a terbinafine film-forming vehicle.
- Regional rights for OTC topical products.
- Co-development with a contract manufacturer.
- Private-label supply agreements.
- Licensing of packaging or metered-dose delivery systems.
- Combination rights with foot-care or dermatology brands.
A deal should define ownership of formulation improvements, manufacturing changes, regulatory filings, trademarks, pharmacovigilance obligations, and territory-specific OTC rights.
What FDA regulatory pathway applies to a new Lamisil formulation?
The pathway depends on dosage form, active concentration, proposed indication, and whether the product is therapeutically equivalent to an existing reference.
| Product concept |
Likely U.S. pathway |
| Equivalent oral terbinafine tablet |
ANDA under section 505(j) |
| Equivalent topical product |
ANDA or applicable OTC pathway |
| Monograph-compliant OTC antifungal |
OTC monograph framework, subject to current FDA requirements |
| New topical delivery system with same active |
NDA or applicable abbreviated pathway, depending on equivalence |
| New indication or materially different dosing |
NDA pathway likely required |
| Pediatric product |
Regulatory pathway depends on formulation and indication |
A topical product with the same active ingredient can still require substantial comparative evidence if the vehicle changes drug release, permeation, local exposure, or clinical performance.
What revenue exposure does the Lamisil patent position create?
The original brand faces high exposure to generic pricing in oral tablets and conventional topical products. Revenue durability depends on brand retention, OTC shelf presence, geographic coverage, and differentiated packaging rather than core patent exclusivity.
| Revenue driver |
Exposure |
| Oral terbinafine tablets |
High generic price pressure |
| Conventional cream |
High private-label and generic pressure |
| Spray and convenience formats |
Moderate pressure |
| Premium film-forming product |
Lower direct comparability |
| Nail-delivery product |
Potentially lower substitution, but higher development cost |
| Brand-based OTC line extensions |
Depends on consumer marketing and retailer access |
A new excipient platform can support higher gross margin only if it produces a visible consumer benefit or clinically meaningful delivery advantage. A formulation that is indistinguishable at the point of use will usually compete on price.
Key Takeaways
- Lamisil contains terbinafine hydrochloride and is available in oral and topical forms across global markets.
- Core terbinafine and conventional Lamisil product exclusivity is largely exhausted in major markets.
- Standard tablet excipients offer limited differentiation potential.
- Topical emulsions, film-forming systems, sprays, and nail-delivery vehicles offer stronger commercial opportunities.
- The best near-term strategy is an improved topical product with better sensory performance, residence time, or application convenience.
- The highest-value technical opportunity is nail delivery, but it has greater clinical and regulatory risk.
- Strong protection should combine formulation, process, device, packaging, and use claims.
- Generic entry risk is high for standard tablets and creams.
- FDA pathway selection depends on whether the product is therapeutically equivalent, monograph-compliant, or materially different from existing terbinafine products.
- Manufacturing know-how may provide greater practical protection than a narrow excipient composition claim.
FAQs
Can excipients extend Lamisil patent protection?
Excipients cannot extend an expired original terbinafine patent. A new formulation may receive separate patent protection if it has novelty, non-obviousness, adequate disclosure, and commercially meaningful claim scope.
Is terbinafine cream a suitable candidate for a preservative-free formulation?
Yes, but the product must demonstrate microbiological control through formulation design, packaging, manufacturing controls, or a validated preservation strategy. Removing benzyl alcohol without replacing its function creates stability and microbial-risk issues.
Can a new Lamisil topical product claim once-daily or single-application treatment?
A dosing claim requires evidence that the formulation maintains adequate local exposure and clinical efficacy at the proposed frequency. A film-forming or deposition-enhancing system may support such a strategy, but the claim cannot rely on excipient selection alone.
What excipient issue is most important for terbinafine nail products?
The critical issue is delivery through or into the nail plate while maintaining terbinafine solubility and acceptable cosmetic properties. Solvent selection, polymer behavior, nail hydration, and permeation enhancement must be evaluated together.
Can a Lamisil follow-on product be sold as an OTC drug in the United States?
A product may qualify for an OTC pathway if its active ingredient, concentration, indication, labeling, and dosage form satisfy applicable FDA requirements. A materially different formulation or claim may require an NDA or another abbreviated regulatory route.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph M005: Antifungal products for over-the-counter human use. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Terbinafine hydrochloride tablets: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. National Library of Medicine. (n.d.). Terbinafine hydrochloride cream: Drug labeling. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Gupta, A. K., Simpson, F. C., & Heller, D. F. (2016). The future of antifungal therapy. Journal of Drugs in Dermatology, 15(5), 561-564.
